AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3983884 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms from a metered dose inhaler)
Number of subjects: 17
Study 29765082 — intervention group
Group type: EXPERIMENTAL
Intervention: Next generation sequencing (NGS)
Number of subjects: 490
Study 29765082 — intervention group
Group type: COMPARATOR
Intervention: Population based Sanger sequencing (PBSS)
Number of subjects: 490
Study 29765082 — intervention group
Group type: EXPERIMENTAL
Intervention: sDRM presence
Number of subjects: 490
Study 27497474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation (CS) program, twice weekly for eight weeks (EG; n=36)
Number of subjects: 71
Study 27497474 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CG; n=35)
Number of subjects: 71
Study 27497474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation (CS) program
Number of subjects: 71
Study 24559642 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearlong multicomponent home-based rehabilitation program
Number of subjects: 81
Study 24559642 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 81
Study 22971882 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered exercise machines incorporating only concentric contractions for 12 weeks
Number of subjects: 53
Study 22971882 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 53
Study 21036491 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 149
Study 21036491 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 149
Study 18159575 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine 3 mg + morphine 50 microg
Number of subjects: 40
Study 18159575 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine 3 mg + morphine 100 microg
Number of subjects: 40
Study 15863536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise
Number of subjects: 52
Study 15863536 — intervention group
Group type: COMPARATOR
Intervention: Home exercise
Number of subjects: 52
Study 15863536 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (operated and nonoperated)
Number of subjects: 52
Study 15863536 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated women
Number of subjects: 52
Study 15863536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training adherence
Number of subjects: 52
Study 15513449 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone sodium succinate (1 gram IV/day for 3 days) followed by oral prednisone (1 mg/kg/day for 11 days) with 4‐day taper (20 mg on day 1, 10 mg on days 2 and 4)
Number of subjects: 0
Study 15513449 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta 1‐a (Avonex 30microg intramuscularly [IM] weekly, or Rebif 22 microg subcutaneously [SQ] weekly)
Number of subjects: 0
Study 15513449 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone alone, without prior treatment with IV methylprednisolone
Number of subjects: 0
Study 15513449 — intervention group
Group type: EXPERIMENTAL
Intervention: IV methylprednisolone treatment followed by oral prednisone
Number of subjects: 0
Study 9537209 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg perorally twice a day for 7 days
Number of subjects: 50
Study 9537209 — intervention group
Group type: COMPARATOR
Intervention: Dipyrone 500 mg perorally three times a day for 7 days
Number of subjects: 50
Study 9398952 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg physostigmine
Number of subjects: 40
Study 9398952 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 40
Study 1760167 — intervention group
Group type: EXPERIMENTAL
Intervention: IM ranitidine 1 mg/kg (n = 15)
Number of subjects: 40
Study 1760167 — intervention group
Group type: EXPERIMENTAL
Intervention: IM ranitidine 2 mg/kg (n = 15)
Number of subjects: 40
Study 1760167 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 40
Study 6114900 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (0.15 mg/kg) plus ranitidine (0.6 mg/kg)
Number of subjects: 8
Study 6114900 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as control)
Number of subjects: 8
Study 6114900 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine plus ranitidine
Number of subjects: 8
Study 31127404 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Screw Retained Arch Bar (SRAB)
Number of subjects: 20
Study 31127404 — intervention group
Group type: COMPARATOR
Intervention: Conventional Erich's Arch Bar (CEAB)
Number of subjects: 20
Study 27631316 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Insertion Technology (RIT)
Number of subjects: 647
Study 27631316 — intervention group
Group type: COMPARATOR
Intervention: Conventional variable stiffness colonoscopes
Number of subjects: 647
Study 24098434 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (≥ 50 years)
Number of subjects: 3316
Study 24098434 — intervention group
Group type: COMPARATOR
Intervention: Younger adults (18-49 years)
Number of subjects: 3316
Study 22339822 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates combined with chemotherapy
Number of subjects: 53
Study 19208456 — intervention group
Group type: EXPERIMENTAL
Intervention: Tat vaccine (7.5microg, 15microg, or 30microg doses)
Number of subjects: 0
Study 19208456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17595890 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg ER (evening)
Number of subjects: 26
Study 17595890 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg ER (morning)
Number of subjects: 26
Study 17595890 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg ER (morning and evening)
Number of subjects: 26
Study 15823775 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% ophthalmic solution (opened group)
Number of subjects: 31
Study 15823775 — intervention group
Group type: COMPARATOR
Intervention: Control group (sealed travoprost 0.004% ophthalmic solution)
Number of subjects: 31
Study 11590531 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer drugs in the NRTI class and nucleotide RT inhibitors
Number of subjects: 0
Study 11590531 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTIs and PIs
Number of subjects: 0
Study 11590531 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug resistance testing
Number of subjects: 0
Study 11590531 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotypic assays
Number of subjects: 0
Study 11590531 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Phenotype
Number of subjects: 0
Study 11590531 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance testing
Number of subjects: 0
Study 9402459 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 10
Study 9402459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8509233 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (6 micrograms daily for 6 months)
Number of subjects: 23
Study 8509233 — intervention group
Group type: COMPARATOR
Intervention: Supportive care (control)
Number of subjects: 23
Study 8509233 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 23
Study 3495194 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion (immediate centrifugation of oxygenator content after termination of cardiopulmonary bypass)
Number of subjects: 292
Study 3495194 — intervention group
Group type: COMPARATOR
Intervention: No autologous transfusion (control group)
Number of subjects: 292
Study 3495194 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion
Number of subjects: 292
Study 3495194 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemonetics software
Number of subjects: 292
Study 31728713 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran 0.3 mg/kg intravenously once every 3 weeks for 18 months
Number of subjects: 225
Study 31728713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 29606543 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP7991 [1 mg, 18.5 kBq (500 nCi)]
Number of subjects: 6
Study 27859700 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session 4-step cognitive-behavioral intervention program
Number of subjects: 22
Study 24469862 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic music video (TMV) intervention
Number of subjects: 113
Study 24469862 — intervention group
Group type: COMPARATOR
Intervention: Low-dose control (audiobooks)
Number of subjects: 113
Study 22360799 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood level in the air trap
Number of subjects: 20
Study 22360799 — intervention group
Group type: COMPARATOR
Intervention: Low blood level in the air trap
Number of subjects: 20
Study 20061355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 20%
Number of subjects: 17
Study 20061355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 18322300 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 35
Study 18322300 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 35
Study 16003451 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (simvastatin) for primary prevention in individuals with TC level higher than 6.2 mmol/L
Number of subjects: 15194
Study 16003451 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (simvastatin) for secondary prevention in individuals with TC level higher than 6.2 mmol/L
Number of subjects: 15194
Study 16003451 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment for all individuals with TC level higher than 6.2 mmol/L
Number of subjects: 15194
Study 16003451 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment for all individuals regardless of TC levels
Number of subjects: 15194
Study 12204809 — intervention group
Group type: EXPERIMENTAL
Intervention: atorvastatin 20, 40, and 80 mg/day
Number of subjects: 86
Study 12204809 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 20, 40, and 80 mg/day
Number of subjects: 86
Study 12204809 — intervention group
Group type: EXPERIMENTAL
Intervention: pravastatin 20, 40, and 80 mg/day
Number of subjects: 86
Study 12204809 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin 20, 40, and 80 mg/day
Number of subjects: 86
Study 12204809 — intervention group
Group type: EXPERIMENTAL
Intervention: fluvastatin 20, 40, and 80 mg/day
Number of subjects: 86
Study 10575423 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 1500
Study 8631045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5-5.0 mg per day
Number of subjects: 33841
Study 1671389 — intervention group
Group type: EXPERIMENTAL
Intervention: Met-GH infusion (80 ng/kg.min)
Number of subjects: 12
Study 1671389 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study 6134041 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing cigarettes
Number of subjects: 24
Study 6134041 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline
Number of subjects: 24
Study 6134041 — intervention group
Group type: COMPARATOR
Intervention: Nicotine-free cigarettes
Number of subjects: 24
Study 6134041 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing tobacco smoke
Number of subjects: 24
Study 31759286 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention (problem-based sessions with cognitive behavioural components)
Number of subjects: 214
Study 31759286 — intervention group
Group type: COMPARATOR
Intervention: Positive control (not specified)
Number of subjects: 214
Study 31759286 — intervention group
Group type: COMPARATOR
Intervention: Negative control (not specified)
Number of subjects: 214
Study 31759286 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention
Number of subjects: 214
Study 30207423 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition (N)
Number of subjects: 3652
Study 30207423 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Water, Sanitation, and Handwashing + Nutrition (WSH + N)
Number of subjects: 3652
Study 30207423 — intervention group
Group type: COMPARATOR
Intervention: Active control (C)
Number of subjects: 3652
Study 29979711 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmer months (temperature increase)
Number of subjects: 1219
Study 29979711 — intervention group
Group type: EXPERIMENTAL
Intervention: Colder months (temperature increase)
Number of subjects: 1219
Study 29979711 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing precipitation in warmer months
Number of subjects: 1219
Study 29979711 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing precipitation in colder months
Number of subjects: 1219
Study 27321488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin treatment (8×10^5 U, twice a day for 7 days)
Number of subjects: 40
Study 27321488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin treatment
Number of subjects: 40
Study 27321488 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 40
Study 24786361 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD treatment
Number of subjects: 17
Study 24786361 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma‐potentiated startle response
Number of subjects: 17
Study 22270199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel vehicle
Number of subjects: 20
Study 22270199 — intervention group
Group type: COMPARATOR
Intervention: Moisturizing lotion (Eucerin Lotion)
Number of subjects: 20
Study 19497591 — intervention group
Group type: COMPARATOR
Intervention: BC
Number of subjects: 22
Study 19497591 — intervention group
Group type: COMPARATOR
Intervention: BC + 5 mg propranolol
Number of subjects: 22
Study 19497591 — intervention group
Group type: COMPARATOR
Intervention: BC + 10 mg propranolol
Number of subjects: 22
Study 19497591 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 22
Study 17464583 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position during the first stage of labor
Number of subjects: 107
Study 17464583 — intervention group
Group type: COMPARATOR
Intervention: Control group (not informed about upright position)
Number of subjects: 107
Study 15700851 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with vincristine (VCR), methotrexate (MTX), and doxorubicin (ADM)
Number of subjects: 106
Study 12704264 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 2
Study 12704264 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 2
Study 12704264 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 2
Study 9839767 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil HCl (5 mg)
Number of subjects: 20
Study 9839767 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 20
Study 7915824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 to 1.0 mg twice weekly)
Number of subjects: 459
Study 7915824 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (2.5 to 5.0 mg twice daily)
Number of subjects: 459
Study 7915824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 459
Study 7915824 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 459
Study 2521641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 15
Study 2521641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1102234 — intervention group
Group type: EXPERIMENTAL
Intervention: dl‐Fenfluramine hydrochloride (240 mg)
Number of subjects: 8
Study 1102234 — intervention group
Group type: EXPERIMENTAL
Intervention: dl‐Fenfluramine hydrochloride (60, 120 mg)
Number of subjects: 8
Study 1102234 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐amphetamine sulfate (20, 40 mg)
Number of subjects: 8
Study 1102234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31977520 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg dexamethasone
Number of subjects: 130
Study 31977520 — intervention group
Group type: COMPARATOR
Intervention: 8 mg dexamethasone
Number of subjects: 130
Study 31094440 — intervention group
Group type: COMPARATOR
Intervention: Skin cancer education (control)
Number of subjects: 1573
Study 31094440 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus a sunscreen activity
Number of subjects: 1573
Study 31094440 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change worksheet (sun protection goal setting and planning)
Number of subjects: 1573
Study 31094440 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized UV damage photograph
Number of subjects: 1573
Study 28372558 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid in serum cholesterol esters (CE) and phospholipids (PL)
Number of subjects: 287
Study 28372558 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitic acid in serum cholesterol esters (CE)
Number of subjects: 287
Study 26066641 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 303
Study 26066641 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture with Manual Stimulation (MA)
Number of subjects: 303
Study 26066641 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture with Electrical and Manual Stimulation (EA)
Number of subjects: 303
Study 23441754 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site pyeloplasty
Number of subjects: 39
Study 23441754 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic pyeloplasty
Number of subjects: 39
Study 21319380 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop in canales sacralis
Number of subjects: 139
Study 21319380 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupotomy dissolution
Number of subjects: 139
Study 21319380 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of canales sacralis drop with acupotomy dissolution
Number of subjects: 139
Study 18632766 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment
Number of subjects: 0
Study 18632766 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16531710 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with UFT
Number of subjects: 0
Study 16531710 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 14966601 — intervention group
Group type: EXPERIMENTAL
Intervention: Shen Yang
Number of subjects: 213
Study 14966601 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 213
Study 11045848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (10^10 CFU) in enterocoated tablets twice a day for 6 months
Number of subjects: 4
Study 8615097 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg for 5 days
Number of subjects: 147
Study 8615097 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg for 5 days
Number of subjects: 147
Study 8615097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 8615097 — intervention group
Group type: COMPARATOR
Intervention: Morphine on the day of operation and placebo for 4 days
Number of subjects: 147
Study 1576061 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt
Number of subjects: 7
Study 1576061 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 7
Study 1576061 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 7
Study 4009494 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicotine (0.75, 1.5 and 3.0 mg/10‐sec infusion)
Number of subjects: 8
Study 4009494 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nicotine (0.4, 1.4 and 2.9 mg estimated yield)
Number of subjects: 8
Study 4009494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham‐smoking)
Number of subjects: 8
Study 30371791 — intervention group
Group type: EXPERIMENTAL
Intervention: BIM23B065 (1.5 mg)
Number of subjects: 63
Study 30371791 — intervention group
Group type: EXPERIMENTAL
Intervention: BIM23B065 (multiple doses)
Number of subjects: 63
Study 30371791 — intervention group
Group type: EXPERIMENTAL
Intervention: BIM23B065 (high dosages)
Number of subjects: 63
Study 30371791 — intervention group
Group type: EXPERIMENTAL
Intervention: BIM23B065 (multiple ascending doses)
Number of subjects: 63
Study 30371791 — intervention group
Group type: EXPERIMENTAL
Intervention: BIM23B065
Number of subjects: 63
Study 30371791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 30094984 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) stimulation of bilateral Hegu(LI 4) and Sanyinjiao(SP 6) for 25 min, combined with medication (mifepristone and misoprostol tablets)
Number of subjects: 60
Study 30094984 — intervention group
Group type: COMPARATOR
Intervention: Medication (mifepristone and misoprostol tablets)
Number of subjects: 60
Study 30094984 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) stimulation of bilateral Hegu(LI 4) and Sanyinjiao(SP 6)
Number of subjects: 60
Study 30094984 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 27268039 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (iTBS) applied to the left premotor cortex
Number of subjects: 15
Study 27268039 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study 25295843 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioscope™ (tactile detection plus Perioscope)
Number of subjects: 26
Study 25295843 — intervention group
Group type: COMPARATOR
Intervention: Tactile explorer (tactile detection alone)
Number of subjects: 26
Study 22447240 — intervention group
Group type: EXPERIMENTAL
Intervention: Effortful swallow with infrahyoid motor electrical stimulation (experimental group, n = 10)
Number of subjects: 20
Study 22447240 — intervention group
Group type: COMPARATOR
Intervention: Effortful swallow with infrahyoid sensory electrical stimulation (control group, n = 10)
Number of subjects: 20